Search Results

BACK FACT-Hep Languages Afrikaans Arabic Bengali Bulgarian Chinese – Simplified Chinese – Traditional Croatian Czech Danish Dutch English Farsi Finnish French German Greek Gujarati Hebrew Hindi Hungarian Italian Japanese Kannada Korean Latvian Lithuanian Malay Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovene Spanish Swedish Tamil Telugu Thai Turkish Urdu Vietnamese Zulu

FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms For patients with Kidney cancer; a 9 item scale of Disease Related Symptoms LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms (FKSI-DRS) is a subset of items derived from the FKSI-15 developed to assess patients’ kidney-cancer-related symptoms. Using patient and expert provider input, the previously developed 15-item index of the most important symptoms and concerns of people being treated for advanced kidney cancer were a mixture of disease-related symptoms and treatment-related side effects. As a result, it may be difficult to assign an informative label to the score defined as the summation of these 15 most important concerns. Because one of the primary goals of treating advanced kidney cancer is the relief of disease-related symptoms, this measure contains nine items predominantly attributable to kidney cancer itself rather than its treatment. It is a reliable, valid, and responsive brief index of the most important symptoms associated with advanced kidney cancer. MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms (FKSI-DRS) VERSION: 4 NUMBER OF ITEMS: 9 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. RELATED MEASURES: FKSI-15 , NFKSI-19 , FKSI-10 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-DRS can be obtained by registering for permission. Users are not permitted to translate the FKSI-DRS without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-DRS may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Butt, Z., Peipert, D., Webster, K., Chen, C., & Cella, D. General population norms for the functional assessment of cancer therapy – kidney symptom index (FKSI). Cancer 2013; 119(2): 429-437. doi: 10.1002/cncr.27688. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Brucker, P., Du, H., Bukowski, R., Vogelzang, N., Bro, W. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health 2007; 10(4): 285-293. doi: 10.1111/j.1524-4733.2007.00183.x. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarzai, J., Rosbrook, B., Kim, S., & Motzer, R. Patient-reported outcomes for axitinib v sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 2013; 108(8): 1571–1578. doi: 10.1038/bjc.2013. Choueiri TK, Powles T, Peltola K, et al. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. Luo, X., Cappelleri, J., Cella, D., Li, J., Charbonneau, C., Kim, S., Chen, I., & Motzer, R. Using the Rasch model to validate and enhance the interpretation of the functional assessment of cancer therapy-kidney symptom index-disease related symptoms scale. Value in Health 2009; 12(4): 580-586. doi: 10.1111/j.1524-4733.2008.00473.x. Motzer, R. , Hutson, T., Olsen, M., Hudes, G., Burke, J., Edenfield, W., Wilding, Agarwal, N., Thompson, J., Cella, D., Bello, A., Korytowksy, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology 2012; 30(12): 1371-1377. doi: 10.1200/JCO.2011.36.4133. Rini, B., Wilding, G., Hudes, G., Stadler, W., Kim, S., Tarazi, J., Rosbrook, B., Trask, P., Wood, L., & Dutcher, J. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 2009; 27(27): 4462-4468. doi: 10.1200/JCO.2008.21.7034. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version LEARN MORE

FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea - 10 item For patients with Dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACIT-Dyspnea is an efficient patient-reported measure of dyspnea severity and related functional limitations for chronic obstructive pulmonary disease, based on a patient-driven PRO conceptual framework. MEASURE NAME: Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item (FACIT-Dyspnea) VERSION: 1 NUMBER OF ITEMS: 10 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scales DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Severity, Functional Limitation TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: PROMIS SF v1.0 – Dyspnea-Severity 10a , PROMIS SF v1.0 – Dyspnea Functional Limitations 10a , PROMIS SF v1.0 – Dyspnea-Severity 5a DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACIT-Dyspnea can be obtained by registering for permission. Users are not permitted to translate the FACIT-Dyspnea without permission from FACIT.org. Permission from FACIT.org to translate the FACIT-Dyspnea may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures PROMIS SF v1.0 – Dyspnea-Severity 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Severity 10a LEARN MORE PROMIS SF v1.0 – Dyspnea Functional Limitations 10a Patient-Reported Outcomes Measurement Information System Short Form - Dyspnea Functional Limitations 10a LEARN MORE PROMIS SF v1.0 – Dyspnea-Severity 5a Patient Reported Outcomes Measurement Information System - Short Form - Dyspnea-Severity 5a LEARN MORE

FAACT Functional Assessment of Anorexia/Cachexia Treatment For patients with Anorexia/Cachexia LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) was designed to measure general aspects of quality of life (QOL) as well as specific anorexia/cachexia-related concerns. It includes the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and a 12 item subscale that specifically measures the symptoms and concerns of patients with anorexia/cachexia (A/CS). The A/CS subscale can be used in conjunction with the FACT-G or as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). Chang et al (2003) has shown this “intensity” rating scale to be essentially equivalent to a “frequency” rating scale (i.e., “none of the time” to “all of the time”). The recall period for each question is “during the past 7 days” and this time frame has been found to provide more precise information than a 4-week time frame (Lai et al 2009). All FACIT scales are scored so that a high score is good. As each of the 12 items of the FAACT anorexia/cachexia-specific subcale ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. All responses are added with equal weight to obtain the total score. In cases where some answers may be missing, a total score is prorated from the score of the answered items, so long as more than 50% of the items (i.e., at least 7 of 12) were answered. The FAACT was developed with input from both patients and clinicians. Semistructured interviews conducted with 10 patients and 5 practitioners generated 32 candidate anorexia/cachexia items (Cella et al 1993). The practitioners who helped generate the items were also later asked to review the entire list of items. The items underwent multiple iterative reviews to reduce redundancy and clarify wording, resulting in a final list of 18 anorexia/ cachexia items. These items were then pilot tested in 10 cancer and 6 HIV-infected patients with anorexia/cachexia. Patients were asked to rate each item in terms of importance (0, not at all important to 4, very important). All items were found to be sufficiently important for retention in the next stage. The FAACT was then validated in a randomized trial comparing 200mg vs. 800mg per day of megestrol acetate oral suspension in 213 patients with cancer (n=155) or HIV (n=58) (Ribaudo et al 2001). The majority of the cancer patients had non small cell lung cancer. The FAACT was administered by computer at baseline and at weeks 4 and 12. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) was administered at weeks 4 and 12 only. The anorexia/cachexia subscale was reduced from 18 to 12 items. Items were removed because they were conceptually dissimilar to eating concerns (e.g., “I have diarrhea”) or minimally correlated with the total score (e.g., “I enjoy eating breakfast”). The Cronbach’s coefficient alpha did not change significantly with removal of those items (from 0.77 for both cancer and HIV patients to 0.76 for cancer and 0.78 for HIV). The correlation between 18-item and 12-item scores was 0.94. Scores on the 12-item subscale significantly differed between groups defined by ECOG PSR and were sensitive to change in PSR. MEASURE NAME: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Cancer patients 18 years and older experiencing anorexia/cachexia RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Anorexia/Cachexia Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: peds FAACT , FACIT-AD , FACIT-AI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAACT can be obtained by registering for permission. Users are not permitted to translate the FAACT without permission from FACIT.org. Permission from FACIT.org to translate the FAACT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Blauwhoff-Buskermolen, S., Ruijgrok, C., Ostelo, R., de Vet, H., Verheul, H., de van der Schueren, M., & Langius, J. The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite. Support Care Cancer 2016; 24: 661–666. doi: 10.1007/s00520-015-2826-2. Change, V., Xia,Q, & Kasimis, B. The Functional Assessment of Anorexia/ Cachexia Therapy (FAACT) Appetite Scale in Veteran Cancer Patients. The Journal of Supportive Oncology 2005; 3(5): 377-382. Gelhorn, H., Gries, K., Speck, R., Duus, E., Bourne, R., Aggarwal, D., & Cella, D. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subcale (A/CS) in lung cancer patients with involuntary weight loss. Quality of Life Research 2019; 28(6): 1641-1653. doi: 10.1007/s11136-019-02135-7. Lai, J-S., Cella, D., Peterman, A., Barocas, J., & Goldman, S. Anorexia/Cachexia related QOL for children with cancer: Testing the psychometric properties of the pediatric functional assessment of anorexia and cachexia therapy (peds-FAACT). Cancer 2005; 104(7): 1531-1539. LeBlanc, T., Samsa, G., Wolf, S., Locke, S., Cella, D., & Abernethy, A. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support Care Cancer 2015; 23: 2341–2347. doi 10.1007/s00520-015-2606-z. Ribaudo, J., Cella, D., Hahn, E., Lloyd, S., Tchekmedyian, N., Von Roenn, J., & Leslie, W. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Quality of Life Research 2001; 1137-1146. Salsman, J., Beaumont, J., Wortman, K., Yan, Y., Friend, J., & Cella, D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Supportive Care in Cancer 2015; 23 (5): 1355-1364. doi: 10.1007/s00520-014-2484-9. Yennurajalingam, S., Frisbee-Hume, S., Palmer, J., Delgado-Guay, M., Bull, J., Phan, A., Tannir, N., Litton, J., Reddy, A., Hui, D., Dalal, S., Massie, L., Reddy, S., & Bruera, E. Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer. Journal of Clinical Oncology 2013; 31(25): 3076-3082doi: 10.1200/JCO.2012.44.4661. Zhou,T., Yang,K., Thapa, S., Fu, Q, Jiang, Y. , & Yu, S. Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia. Support Care Cancer 2017; 25: 1183–1189. doi: 10.1007/s00520-016-3508-4. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., & Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., & Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures peds FAACT Pediatric Functional Assessment of Anorexia/Cachexia Treatment LEARN MORE FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index LEARN MORE

FACT-BRM Functional Assessment of Cancer Therapy - Biologic Response Modifiers For patients receiving Biologic Response Modifiers LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Biological Response Modifier (FACT-BRM) measures quality of life in cancer patients who are receiving treatment with biologic response modifiers. Using the FACT-G as a base, 17 additional items related to symptoms common to interferon and retinoid therapy were developed. Data collected at baseline (n = 191) and week 2 (n = 168) in a randomized trial of interferon ±13-cis-retinoic acid in advanced renal cell carcinoma patients were used to validate the instrument. Using a combined empirical and conceptual approach, the 17 items were reduced to 13 items consisting of two subscales: ‘BRM-physical’ (7 items) and ‘BRM-mental’ (6 items). Internal consistency of the trial outcome index (TOI) combining physical well-being, functional well-being and the BRM subscales, was 0.91 for baseline assessments and 0.92 for week 2. Discriminant validity was demonstrated for the TOI by its ability to differentiate among prognostic risk groups, and for the total FACT-G, TOI and total FACT–BRM scores by their ability to distinguish between groups differing in performance, response and toxicity status. MEASURE NAME: Functional Assessment of Cancer Therapy - Biologic Response Modifiers (FACT-BRM) VERSION: 4 NUMBER OF ITEMS: 40 PATIENT POPULATION: Cancer patients 18 years and older receiving treatment with biological response modifiers RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, BRM-Physical, BRM-Mental TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-BMT , FACT/GOG-NTX , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-BRM can be obtained by registering for permission. Users are not permitted to translate the FACT-BRM without permission from FACIT.org. Permission from FACIT.org to translate the FACT-BRM may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bacik, J., Mazumdar, M., Murphy, B., Fairclough, D., Eremenco, S., Mariani, T., Motzer, R., & Cella, D. The functional assessment of cancer therapy-BRM (FACT-BRM): A new tool for the assessment of quality of life in patients treated with biologic response modifiers. Quality of Life Research 2004; 13(1): 137-154. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-BMT Functional Assessment of Cancer Therapy - Bone Marrow Transplantation LEARN MORE FACT/GOG-NTX Functional Assessment of Cancer Therapy/Gynecologic Oncology Group – Neurotoxicity LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

FACT-M Functional Assessment of Cancer Therapy – Melanoma For patients with melanoma LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview A systematic review of the literature on quality of life in melanoma patients suggested an overwhelming need for a disease-specific subscale. The Functional Assessment of Cancer Therapy (FACT–Melanoma) was developed to meet this need. This instrument was developed in three stages. In stage I, the literature was comprehensively reviewed, and over 300 cancer-specific items from the Functional Assessment of Chronic Illness Therapy (FACIT) item bank were examined to identify items of potential relevance to melanoma patients. In stage II, 20 melanoma experts identified questions that were relevant to melanoma patients to be included in a pilot questionnaire. In stage III, the pilot measure and a semi-structured interview to assess item comprehension, relevance, and overall content were administered to 40 patients with various stages of melanoma. In all, 97 items were culled from the literature and the FACIT item bank; after items were reviewed and evaluated. After final revisions were made, the FACT-M tool included 24 items encompassing three QOL domains: 20 items relate to physical well-being, 3 to emotional well-being, and 1 to social well-being. The face and content validity of the FACT–M was confirmed in melanoma patients and by professionals. MEASURE NAME: Functional Assessment of Cancer Therapy – Melanoma (FACT-M) VERSION: 4 NUMBER OF ITEMS: 51 PATIENT POPULATION: Melanoma patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Melanoma Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FACT-B DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-M can be obtained by registering for permission. Users are not permitted to translate the FACT-M without permission from FACIT.org. Permission from FACIT.org to translate the FACT-M may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Askew, R., Xing, Y., Plamer, J., Cella, D., Moye, L., & Cormier, J. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value in Health 2009; 12(8): 1144–1150. doi: 10.1111/j.1524-4733.2009.00570.x. Bharmal, M. Fofana, F., Barbosa, C., Williams, P., Mahnke, L., Marrel, A., & Schlichting, M. Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. Health and Quality of Life Outcomes 2017; 15:247. doi: 10.1186/s12955-017-0815-5. Bagge, AS.L., Ben-Shabat, I., Belgrano, V. et al. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. Ann Surg Oncol 23, 2062–2069 (2016). https://doi.org/10.1245/s10434-016-5103-9 Cormier, J., Davidson, L, Webster, K., Cella, D., Xing, Y., Ross, M., Gershenwald, J., Lee, J., Mansfield, P., Camacho, L., Kim, K., Papadopoulos, N., & Palmer, J. Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma (FACT-Melanoma) questionnaire. Cancer 2008; 112(10): 2249-2257. doi: 10.1002/cncr.23424. Cormier, J., Davidson, L., Xing, Y., Webster, K., & Cella, D. Measuring quality of life in patients with melanoma: Development of the FACT-Melanoma subscale. Journal of Supportive Oncology 2005; 3(2): 139-145. Lindqvist Bagge AS, Wesslau H, Cizek R, Holmberg CJ, Moncrieff M, Katsarelias D, Carlander A, Olofsson Bagge R. Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. Eur J Surg Oncol. 2021 Sep 20:S0748-7983(21)00739-3. doi: 10.1016/j.ejso.2021.09.013. Epub ahead of print. PMID: 34600786. Robinson, D., Cormier, J., Zhao, N., Uhlar, C., Revicki, D., & Cella, D. Health-related quality of life among patients with metastatic melanoma: results from an international Phase 2 multicenter study. Melanoma Research 2012; 22(1):54–62. doi: 10.1097/CMR.0b013e32834d3da0. Swartz, R., Baum, G., Askew, R., Palmer, J., Ross, M., & Cormier, J. Reducing patient burden to the FACT-Melanoma quality-of-life questionnaire. Melanoma research 2012; 22(2): 158-63. doi: 10.1097/CMR.0b013e3283511dbf. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version LEARN MORE FACT-B Functional Assessment of Cancer Therapy – Breast LEARN MORE

peds FACIT-F Pediatric Functional Assessment of Chronic Illness Therapy – Fatigue Pediatric - Functional Assessment of Chronic Illness Therapy-Fatigue LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The 13-item Peds FACIT-F was developed via literature review, feedback from patients, parents, and clinicians, and a face-to-face consensus meeting. Its reliability and validity were examined on the basis of data from 159 pediatric patients with cancer via classical test theory and Rasch analysis. Results showed that the Peds FACIT-F demonstrated good internal consistency, acceptable item-total correlations, and met the unidimensionality assumption set by confirmatory factor analysis. All items had acceptable fit statistics in the Rasch analysis and demonstrated stable measurement properties by age, sex, and cancer type. Scores on the Peds FACIT-F significantly discriminated between patients with and without anemia and among patients with different functional status; clinically relevant minimally important differences were estimated accordingly. The Peds FACIT-F was significantly correlated to the PedsQL Multidimensional Fatigue Scale. MEASURE NAME: Pediatric Functional Assessment of Chronic Illness Therapy – Fatigue (peds FACIT-F) VERSION: 1 NUMBER OF ITEMS: 13 PATIENT POPULATION: Pediatric cancer patients 8-18 years old RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Fatigue TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. RELATED MEASURES: FACIT-Fatigue , FACIT-F , FACT-An DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the peds FACIT-F can be obtained by registering for permission. Users are not permitted to translate the peds FACIT-F without permission from FACIT.org. Permission from FACIT.org to translate the peds FACIT-F may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Fernandes, K., Teixeira, B., Arnold, B., Mendonça, T., Oliveira, S., & daSilva, C. Cross-cultural adaptation and validation of the universal Portuguese-version of the Pediatric Functional Assessment of Chronic Illness Therapy – Fatigue (pedsFACIT-F)Adaptação transcultural e validação da versão portuguesa universal da Escala Avaliação Funcional Pediátrica de Terapia de Doença Crônica – Fadiga (pedsFACIT-F). Jornal de Pediatria 2019; 796: 1-8. doi: 10.1016/j.jped.2019.01.003. Lai, J-S., Cella, D., Kupst, MJ, Holm, S., Kelly, M., Bode, R., & Goldman, S. Measuring fatigue for children with cancer: development and validation of the pediatric Functional Assessment of Chronic Illness Therapy-Fatigue (pedsFACIT-F). Journal of Pediatric Hematology and Oncology 2007; 29(7): 471-479. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Fatigue Functional Assessment of Chronic Illness Therapy – Fatigue Scale LEARN MORE FACIT-F Functional Assessment of Chronic Illness Therapy – Fatigue LEARN MORE FACT-An Functional Assessment of Cancer Therapy – Anemia LEARN MORE

BACK FACT-G Languages Afrikaans Albanian Arabic Armenian Bengali Bosnian Bulgarian Burmese Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French Georgian German Greek Gujarati Haitian Creole Hebrew Hiligaynon Hindi Hungarian Icelandic Ilokano Indonesian Italian Japanese Kannada Kazakh Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Mongolian Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Sinhala Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

BACK FACT-GP Languages Albanian Afrikaans Arabic Armenian Bengali Bosnian Bulgarian Burmese Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French Georgian German Greek Gujarati Haitian Creole Hebrew Hiligaynon Hindi Hungarian Icelandic Ilokano Indonesian Italian Japanese Kannada Kazakh Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Mongolian Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Sinhala Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

BACK FANLTC Languages Albanian Afrikaans Arabic Armenian Bengali Bosnian Bulgarian Burmese Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French Georgian German Greek Gujarati Haitian Creole Hebrew Hiligaynon Hindi Hungarian Icelandic Ilokano Indonesian Italian Japanese Kannada Kazakh Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Mongolian Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Sinhala Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

BACK FACT-G7 Languages Afrikaans Albanian Arabic Armenian Assamese Bengali Bosnian Bulgarian Burmese Catalan Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French Georgian German Greek Gujarati Haitian Creole Hebrew Hiligaynon Hindi Hungarian Icelandic Ilokano Indonesian Italian Japanese Kannada Kazakh Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Mongolian Montenegrin Norwegian Odia Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Sesotho Setswana Sinhala Slovak Slovene Spanish Swahili Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

BACK FACIT-TB Languages Arabic English Indonesian Sinhala Tagalog Urdu